ProMIS Neurosciences Inc. (TSX:PMN; OTCQB:ARFXF) is pleased to announce that it closed yesterday a private placement of 19,306,668 Units at the price of CDN$0.375 per Unit for gross proceeds of approximately CDN$ 7,240,000.
OSG chief executive Sam Norton tells Noble Capital conference that gains over last five months appear to be holding up. The first signs of a recovery may be showing for tanker rates in the recently slumping US Jones Act market.
Finance experts say dry bulk sector is most favourable starting point in 2018 - but they are not exactly issuing guarantees as mergers may be the flavour of the year
Gray Television, Inc. (NYSE: GTN and GTN.A) announced today that it has completed its previously announced and priced underwritten public offering of shares of its common stock at a price to the public of $14.50 per share.
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the underwriters of its previously announced underwritten public offering have exercised their option to purchase an additional 2,100,000 shares.
Boutique bank appoints veteran oil and energy specialist as its prepares for US roadshows
Noble Capital has taken its next step towards entering the US capital markets by hiring an equity analyst with extensive experience in the oil and energy sectors. Speaking to TradeWinds on the sidelines of this week’s Capital Link Maritime Forum in New York, Poe Fratt said Noble was gearing up to launch coverage within 2017.
NOBLE Life Science Partners (NOBLE LSP), a division of Noble Capital Markets Inc. welcomes Camillo Ricordi, M.D. to its Scientific Advisory Board (SAB)
Kratos Defense & Security Solutions, Inc. (“Kratos”) (Nasdaq:KTOS), announced today the pricing of an underwritten offering of 14,000,000 shares of its common stock at a public offering price of $12.25 per share.
Noble Capital Markets, Inc., acting as the exclusive placement agent for subscribers residing in the United States,
NOBLE Capital Markets, a leading small-cap focused investment firm, announces the initiation of research coverage of Vectrus Inc.
With the traditional players exiting the sector or gravitating towards the mega-owners, Noble Capital has spotted a gap in the market
Noble Capital Markets announced today that it has initiated research coverage on Marlin Gold Ltd. (TSXV: MLN.V, OTCQX: MLNGF). The report was issued by Senior Research Analyst, Michael Heim, CFA.
Noble Capital Markets announced today that it has initiated research coverage on AAR Corp. (AIR). The report was issued by Research Analyst, Benjamin Klieve, CFA.
Noble Capital Markets (Noble) announced today that it will host its Fourth Annual Media, Finance and Investor Program produced in Partnership with the National Association of Broadcasters (NAB) to be held at the Las Vegas Convention Center (LVCC), April 24-25, 2017.
Noble Capital Markets announced today that it has initiated research coverage on DLH Holdings Corp. (DLHC). The report was issued by Senior Research Analyst, Mark Jordan, CFA.
Noble Capital Markets announced today that it has initiated research coverage on ESSA Pharma Inc. (EPIX). The report was issued by Noble's Head of Biotechnology Research, Kumar Raja, PhD.
Noble Capital Markets announced today that it has initiated research coverage on Endeavour Silver Corp. (EXK). The report was issued by Senior Research Analyst, Michael Heim, CFA.
Noble Life Science Partners, a division of Noble Financial Capital Markets (Noble) announced today that Nathan Cali, formerly Noble’s specialty pharmaceuticals senior analyst, has moved to its investment banking department.
Noble Life Science Partners, a division of Noble Financial Capital Markets (Noble) announced today that Cynapsus Therapeutics, Inc. (Cynapsus – NASADQ;CYNA) will no longer attend its fourth consecutive Noble Investor Conference - NobleCon13 to be held at the Boca Raton Resort & Club, January 30-31, 2017 – as it has been acquired by Sunovion Pharmaceuticals, at a purchase price of $624 million USD ($820 million CND). Noble was the first to initiate equity research coverage on Cynapsus and has supported the company’s growth through three rounds of financing totaling in excess of $100 million USD.